How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

SGLT2 Inhibitors in Stage 5 Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cardiovascular and Kidney Outcomes

calendar_today November 13, 2026 person Ahmed, H. M., Rehman, U. u., Owais, M. domain medrxiv

Background: Evidence supporting sodium-glucose cotransporter-2 (SGLT2) inhibitor use in stage 5 chronic kidney disease (CKD) remains limited because major randomized trials have largely excluded this population. We evaluated associations between SGLT2 inhibitor use and cardiovascular and kidney outcomes in patients with stage 5 CKD. Methods: We systematically searched PubMed, Scopus, Cochrane CENTRAL, and Google Scholar through April 10, 2026.

open_in_new Read original post